Status:
UNKNOWN
Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT
Lead Sponsor:
University of Siena
Collaborating Sponsors:
IBSA Institut Biochimique SA
Conditions:
Thyroiditis Autoimmune
Eligibility:
FEMALE
18-65 years
Phase:
PHASE2
Brief Summary
Over the past 10 years, several clinical studies have suggested that selenium supplementation may influence the natural history of AIT. Recently, Interferon gamma (IFNγ)-inducible chemokines (CXCL-9, ...
Eligibility Criteria
Inclusion
- Diagnosis of chronic autoimmune thyroiditis defined by positivity of anti thyroperoxidase and/or anti thyroglobulin antibodies (\> or = 100 U/l) and thyroid hypoechogenicity
Exclusion
- Presence of other thyroid disease but micronodules
- History of the malignancy in the past 5 years
- Drugs affecting immune system and/or thyroid function
- Pregnancy detected during screening or follow-up.
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02302768
Start Date
December 1 2012
End Date
January 1 2015
Last Update
November 27 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.